In Vitro Skin Model for Contact Allergy Sensitization Evaluation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating the sensitizing potential of chemical compounds in products like perfumes and cosmetics are inadequate, particularly in distinguishing between irritation and sensitization, and often rely on animal testing, which is being phased out due to environmental restrictions, and existing skin models are insufficient for analyzing sensitizing responses.
Innovation Solution
A method involving the use of specific biomarkers, such as BRAK, CTSS, HSP27, IL18, and others, to assess the expression levels in skin samples to determine the sensitizing potential of a test compound, utilizing an in vitro approach with reconstructed skin models like EPISKIN, without the need for additional cells or complex cell types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If animal testing methods (LLNA) are used to evaluate sensitizing potential, then reliable identification of skin sensitizing molecules is achieved, but animal welfare is compromised and regulatory restrictions are violated
Solution Approach 1:
The patent creates an in vitro skin model that copies the essential biological functions of human skin, specifically using reconstructed epidermis with keratinocytes to simulate skin sensitization responses. This model replicates the skin's immune response mechanisms without requiring animal subjects, thereby maintaining identification reliability while eliminating animal welfare concerns.
Solution Approach 2:
The patent introduces an intermediary measurement system that detects sensitization through gene expression analysis (specifically IL-8 and TNF-alpha markers) rather than direct animal observation. This intermediary biochemical assay serves as a mediator between the test compound and the evaluation outcome, providing reliable data without animal involvement.
2Device complexity
If traditional skin models are used for sensitization analysis, then simplicity is maintained, but measurement precision for sensitizing responses is insufficient
Solution Approach 1:
The patent enhances the skin model's measurement capability by monitoring specific gene expression parameters (IL-8, TNF-alpha) at defined time points (6 and 24 hours) after compound exposure. This parameter-based approach transforms the simple skin model into a precise sensitization detection system by quantifying specific biochemical markers of immune response.
Solution Approach 2:
The patent replaces direct observation of skin reactions with molecular-level detection methods, substituting mechanical/visual assessment with biochemical analysis of gene expression. This substitution enables precise measurement of sensitization responses through molecular markers while maintaining the simplicity of the in vitro skin model structure.
3Measurement precision
If six specific gene markers are monitored in skin samples, then sensitizing potential evaluation accuracy is improved, but analysis complexity increases
Solution Approach 1:
The patent segments the complex sensitization evaluation into six specific gene marker analyses (IL-8, TNF-alpha and four additional markers) that can be measured independently through PCR or microarray techniques. This segmentation allows precise evaluation of sensitization potential while enabling parallel processing of multiple markers, thereby managing analysis complexity through systematic division of the measurement task.
Data Source
AI summary
The invention relates to a method for evaluating the sensitizing potential of a test compound, and to a kit for implementing said method.